Catalogo Articoli (Spogli Riviste)

OPAC HELP

Titolo:
Marked reduction in the incidence of hepatic veno-occlusive disease after allogeneic hematopoietic stem cell transplantation with CD34(+) positive selection
Autore:
Moscardo, F; Sanz, GF; de la Rubia, J; Jimenez, C; Saavedra, S; Regadera, A; Andreu, R; Garcia, I; Plume, G; Martinez, J; Martin, G; Jarque, I; Sanz, MA;
Indirizzi:
Hosp Univ La Fe, Dept Hematol, Bone Marrow Transplant Unit, Valencia 46009, Spain Hosp Univ La Fe Valencia Spain 46009 nsplant Unit, Valencia 46009, Spain
Titolo Testata:
BONE MARROW TRANSPLANTATION
fascicolo: 9, volume: 27, anno: 2001,
pagine: 983 - 987
SICI:
0268-3369(200105)27:9<983:MRITIO>2.0.ZU;2-L
Fonte:
ISI
Lingua:
ENG
Soggetto:
BONE-MARROW TRANSPLANTATION; VERSUS-HOST DISEASE; VENOOCCLUSIVE-DISEASE; EUROPEAN GROUP; BREAST-CANCER; RISK-FACTORS; LIVER; BLOOD; DIAGNOSIS; LEUKEMIA;
Keywords:
CD34(+) selection; allogeneic hematopoietic stem cell transplantation; hepatic veno-occlusive disease;
Tipo documento:
Article
Natura:
Periodico
Settore Disciplinare:
Clinical Medicine
Life Sciences
Citazioni:
31
Recensione:
Indirizzi per estratti:
Indirizzo: Sanz, MA Hosp Univ La Fe, Dept Hematol, Bone Marrow Transplant Unit, Av Campanar 21, Valencia 46009, Spain Hosp Univ La Fe Av Campanar 21 Valencia Spain 46009 46009, Spain
Citazione:
F. Moscardo et al., "Marked reduction in the incidence of hepatic veno-occlusive disease after allogeneic hematopoietic stem cell transplantation with CD34(+) positive selection", BONE MAR TR, 27(9), 2001, pp. 983-987

Abstract

Veno-occlusive disease of the liver (VOD) is a common and severe complication of allogeneic hematopoietic stem cell transplantation (HSCT), To determine the incidence of, and the risk factors for the development of VOD, we performed a retrospective analysis of a series of 178 patients, who underwent allogeneic HSCT at our institution between 1990 and 1999, Busulfan and cyclophosphamide constituted the conditioning regimen most frequently administered. Bone marrow was the source of stem cells in 129 patients (73%), and peripheral blood (PBSC) in 49 patients (27%), Thirty-one patients of the PBSC group received CD34(+) positively selected grafts. Most patients were given cyclosporin A and methotrexate (MTX) as graft-versus-host disease (GVHD) prophylaxis. Overall, 30 patients (17%) developed VOD, In univariate analyses, the incidence of VOD was significantly higher in recipients of unmanipulated grafts (20% vs 0%; P=0.01), in patients with active malignant disease at transplantation (24% vs 9%; P = 0.03), in recipients of marrow from unrelated donors (33% vs 15%; P = 0.03), in patients grafted with bone marrow (21% vs 6%; P = 0.03), and in those receiving MTX as GVHD prophylaxis (21% vs 6%; P = 0.05), Under multivariate analysis, only CD34(+) positive selection (P = 0.0004) and the status of the disease at transplant (P = 0.03) were statistically significant variables for the development of VOD, We conclude that CD34(+) positively selected PBSC transplantation could result in a marked reduction in the incidence of VOD after allogeneic HSCT.

ASDD Area Sistemi Dipartimentali e Documentali, Università di Bologna, Catalogo delle riviste ed altri periodici
Documento generato il 27/09/20 alle ore 12:58:52